A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden identifier:
NCT03668119 (


Study Contact Information:

Please contact the sites directly. If there is no contact information, email [email protected]

About this Study

This study is researching immunotherapy drugs for treating advanced cancers. The researchers are studying whether treatment with a combination of the drugs nivolumab plus ipilimumab is safe and effective compared with nivolumab alone.  

This study is also researching whether a tumor test called "tumor mutational burden" (TMB) can help doctors tell how well patients will respond to immunotherapy drugs.

NOTE: This study is no longer enrolling.

Type of Study

This is a randomized, two-arm study. 

What the Study Entails

This Study is Open To:

NOTE: This study is no longer enrolling.

This Study is Not Open To:

NOTE: This study is no longer enrolling.


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.